Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2021 | Highlights from AAIC: Targeting the immune response to treat AD

Jacobo Mintzer • 5 Aug 2021
AAIC 2021
Alzheimer’s Disease Dementia

Jacobo E. Mintzer, MD, of the Medical University of South Carolina, discusses the emphasis on inflammation and the immune response in the treatment of Alzheimer’s disease (AD), seen at the 2021 Alzheimer’s Association International Conference (AAIC). He notes that several studies were presented looking at new potential targets for the treatment of AD, based on better management of the immune response. This interview took place during the Alzheimer’s Association International Conference (AAIC), 2021.

Disclosures

Prof. Mintzer reports the following disclosures:
AARP – Global Council on Brain Health, AARP – Staying Sharp, ACADIA, ACTC/ATRI, Alzheimer’s Association (local and national), BioPharma Connex, Cerevel Therapeutics, Genentech Pharmaceuticals, International Psychogeriatric Association, NeuroQuest, Praxis Pharmaceuticals, Recruitment Partners LLC, Technology Accelerator Company, Elder Court.

More from Jacobo Mintzer

7:14
Phase III ADMET2 trial of methylphenidate for apathy in Alzheimer's Disease
Jacobo Mintzer • 5 Aug 2021

Related Videos

3:58
Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease
Madison Honey • 7 Mar 2024
4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024
4:44
Influence of genetic risk for psychiatric disorders on dementia
Jenna Najar • 6 Mar 2024
2:31
Barriers to dementia treatment: awareness, accessibility, and affordability
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals